Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada
Background: Many patients with advanced follicular lymphoma (FL) and marginal zone lymphoma (MZL) relapse after first-line chemotherapy. Objective: To examine healthcare resource utilization (HCRU) and cost, treatment patterns, progression, and survival of patients with FL and MZL who relapse after...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/5/352 |
| _version_ | 1797600459313119232 |
|---|---|
| author | John Kuruvilla Emmanuel M. Ewara Julia Elia-Pacitti Ryan Ng Maria Eberg Atif Kukaswadia Arushi Sharma |
| author_facet | John Kuruvilla Emmanuel M. Ewara Julia Elia-Pacitti Ryan Ng Maria Eberg Atif Kukaswadia Arushi Sharma |
| author_sort | John Kuruvilla |
| collection | DOAJ |
| description | Background: Many patients with advanced follicular lymphoma (FL) and marginal zone lymphoma (MZL) relapse after first-line chemotherapy. Objective: To examine healthcare resource utilization (HCRU) and cost, treatment patterns, progression, and survival of patients with FL and MZL who relapse after first-line treatment, in Ontario, Canada. Methods: A retrospective, administrative data study identified patients with relapsed FL and MZL (1 January 2005–31 December 2018). Patients were followed for up to three years post relapse to assess HCRU, healthcare costs, time to next treatment (TTNT), and overall survival (OS), stratified by first- and second-line treatment. Results: The study identified 285 FL and 68 MZL cases who relapsed after first-line treatment. Average duration of first-line treatment was 12.4 and 13.4 months for FL and MZL patients, respectively. Drug (35.9%) and cancer clinic costs (28.1%) were major contributors to higher costs in year 1. Three-year OS was 83.9% after FL and 74.2% after MZL relapse. No statistically significant differences were observed in TTNT and OS between patients with FL who received R-CHOP/R-CVP/BR in the first line only versus both the first- and second- line. A total of 31% of FL and 34% of MZL patients progressed to third-line treatment within three years of initial relapse. Conclusion: Relapsing and remitting nature of FL and MZL in a subset of patients results in substantial burden to patients and the healthcare system. |
| first_indexed | 2024-03-11T03:49:25Z |
| format | Article |
| id | doaj.art-23482e06a567402e8638f4a656a8694c |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T03:49:25Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-23482e06a567402e8638f4a656a8694c2023-11-18T01:01:30ZengMDPI AGCurrent Oncology1198-00521718-77292023-04-013054663467610.3390/curroncol30050352Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, CanadaJohn Kuruvilla0Emmanuel M. Ewara1Julia Elia-Pacitti2Ryan Ng3Maria Eberg4Atif Kukaswadia5Arushi Sharma6Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2C1, CanadaMarket Access, Janssen Canada Inc., 19 Green Belt Drive, North York, ON M3C 1L9, CanadaMedical Affairs, Janssen Canada Inc., 19 Green Belt Drive, North York, ON M3C 1L9, CanadaReal World Solutions, IQVIA, 16720 Rte Transcanadienne, Kirkland, QC H9H 5M3, CanadaReal World Solutions, IQVIA, 16720 Rte Transcanadienne, Kirkland, QC H9H 5M3, CanadaReal World Solutions, IQVIA, 300-6700 Century Avenue, Mississauga, ON L5N 6A4, CanadaReal World Solutions, IQVIA, 535 Legget Drive, Tower C, 7th Floor, Ottawa, ON K2K 3B8, CanadaBackground: Many patients with advanced follicular lymphoma (FL) and marginal zone lymphoma (MZL) relapse after first-line chemotherapy. Objective: To examine healthcare resource utilization (HCRU) and cost, treatment patterns, progression, and survival of patients with FL and MZL who relapse after first-line treatment, in Ontario, Canada. Methods: A retrospective, administrative data study identified patients with relapsed FL and MZL (1 January 2005–31 December 2018). Patients were followed for up to three years post relapse to assess HCRU, healthcare costs, time to next treatment (TTNT), and overall survival (OS), stratified by first- and second-line treatment. Results: The study identified 285 FL and 68 MZL cases who relapsed after first-line treatment. Average duration of first-line treatment was 12.4 and 13.4 months for FL and MZL patients, respectively. Drug (35.9%) and cancer clinic costs (28.1%) were major contributors to higher costs in year 1. Three-year OS was 83.9% after FL and 74.2% after MZL relapse. No statistically significant differences were observed in TTNT and OS between patients with FL who received R-CHOP/R-CVP/BR in the first line only versus both the first- and second- line. A total of 31% of FL and 34% of MZL patients progressed to third-line treatment within three years of initial relapse. Conclusion: Relapsing and remitting nature of FL and MZL in a subset of patients results in substantial burden to patients and the healthcare system.https://www.mdpi.com/1718-7729/30/5/352burden of illnessfollicular lymphomamarginal zone lymphomacostsepidemiology |
| spellingShingle | John Kuruvilla Emmanuel M. Ewara Julia Elia-Pacitti Ryan Ng Maria Eberg Atif Kukaswadia Arushi Sharma Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada Current Oncology burden of illness follicular lymphoma marginal zone lymphoma costs epidemiology |
| title | Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada |
| title_full | Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada |
| title_fullStr | Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada |
| title_full_unstemmed | Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada |
| title_short | Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada |
| title_sort | estimating the burden of illness of relapsed follicular lymphoma and marginal zone lymphoma in ontario canada |
| topic | burden of illness follicular lymphoma marginal zone lymphoma costs epidemiology |
| url | https://www.mdpi.com/1718-7729/30/5/352 |
| work_keys_str_mv | AT johnkuruvilla estimatingtheburdenofillnessofrelapsedfollicularlymphomaandmarginalzonelymphomainontariocanada AT emmanuelmewara estimatingtheburdenofillnessofrelapsedfollicularlymphomaandmarginalzonelymphomainontariocanada AT juliaeliapacitti estimatingtheburdenofillnessofrelapsedfollicularlymphomaandmarginalzonelymphomainontariocanada AT ryanng estimatingtheburdenofillnessofrelapsedfollicularlymphomaandmarginalzonelymphomainontariocanada AT mariaeberg estimatingtheburdenofillnessofrelapsedfollicularlymphomaandmarginalzonelymphomainontariocanada AT atifkukaswadia estimatingtheburdenofillnessofrelapsedfollicularlymphomaandmarginalzonelymphomainontariocanada AT arushisharma estimatingtheburdenofillnessofrelapsedfollicularlymphomaandmarginalzonelymphomainontariocanada |